MedTrace Logo

Selenium Supplementation of Patients With Cirrhosis

NCT00212212 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2012-03-07

No results posted yet for this study

Summary

This study is being conducted to determine if patients with cirrhosis (liver disease) are selenium deficient. The effect of supplementation with two chemical forms of selenium on plasma selenium biomarkers will be determined and correlated with the severity of the liver disease.

Conditions

  • Cirrhosis

Interventions

DIETARY_SUPPLEMENT

selenium

200 µg selenium as selenate

DIETARY_SUPPLEMENT

selenium

400 µg selenium as selenate

DIETARY_SUPPLEMENT

selenium

200 µg selenium as selenomethionine

DIETARY_SUPPLEMENT

placebo

placebo tablet

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Raymond F Burk, M.D. · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212212 on ClinicalTrials.gov